26 January 2016 - Uptravi is indicated for the long-term treatment of idiopathic pulmonary arterial hypertension (iPAH), heritable pulmonary arterial hypertension (HPAH), PAH associated with connective tissue disorders and PAH associated with congenital heart disease, in adult patients with WHO functional class (FC) II-III to delay disease progression.

For more details, go to: http://www1.actelion.com/en/our-company/news-and-events.page?newsId=1981215&bb=js